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Long non-coding RNAs (lncRNAs) can serve as promising biomarkers and therapeutic targets in 
cancer. However, their roles in regulating cancer drug response have not gained much momentum.  
By integrating multiple dimensional pharmacogenomic data of 11,950 lncRNAs in 5,605 
tumors and 1,005 cancer cell lines, I first investigated how the cancer cell lines can recapitulate 
the genomic and epigenetic alterations of lncRNAs in primary tumor patients. Next, I built 
lncRNA-drug response models for 265 anti-cancer agents across 27 cancer types based on Elastic 
Net (EN) regression and bootstrap aggregation. This analysis identified a landscape of 162,327 
lncRNA-drug interactions, yielding more than 1,000 lncRNA-based EN drug response prediction 
(LENP) models in pan-cancer and cancer-specific scales. The LENP models are further applied 
for 49 FDA approved drugs to TCGA patient samples from 21 cancer types. A multivariate cox 
regression is implemented to show that cancer cell line derived LENP models could predict the 
therapeutic outcome in patients with stomach, thyroid, breast, and colorectal cancer. To extend the 
knowledge of how lncRNAs regulate the drug resistance in cancer, I designed an lncRNA-pathway 
co-expression analysis and suggested that lncRNAs could regulate drug response through drug-
metabolism or drug-target pathways. Finally, I conducted the RNA-seq analysis and 
experimentally validated that EPIC1, the top predictive lncRNA for the BET inhibitors, strongly 
promotes iBET762 and JQ-1 resistance in breast cancer through activating MYC transcriptional 
activity. 
Systematic Identification of Non-coding Pharmacogenomic Interactions in Cancer 
Yue Wang, M.S. 
University of Pittsburgh, 2018
 
 v 
To our best knowledge, this thesis represents the first large-scale systematic study to link 
noncoding genotypes with drug response phenotypes in both cancer cell lines and primary tumors. 
The landscape of lncRNA-drug interactions should serve as a comprehensive knowledgebase for 
the identification of non-coding biomarkers for cancer precision therapy. 
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1.0  INTRODUCTION 
Heterogeneous response to cancer therapies between individuals has been largely attributed 
to genetic difference of tumor cells[1]. Using cell-line based panels annotated with 
pharmacogenomic data, efforts on protein coding genes have led to many insightful discoveries[2], 
as well as new questions: few new biomarkers and drivers were identified to fully explain the 
complicated process that regulates drug resistance in cancer[3, 4].  
Emerging evidence from large-scale studies, such as the Encyclopedia of DNA Elements 
(ENCODE), suggest that up to 80% of the human genome is capable of being transcribed into 
primary RNA transcripts, but the majority of them are non-coding genes that do not encode protein 
products. One big class of these non-coding genes is the long non-coding RNAs (lncRNAs) [5, 6]. 
Due to the dearth of genomics/epigenetic platforms covering the non-coding region of the human 
genome, lncRNAs’ role in cancer drug response has not gained much momentum. This thesis 
would integrate the pharmacogenomics data from both primary tumor and cancer cells to 
investigate how lncRNAs would mechanistically regulate anti-cancer drug response. Using a 
machine-learning based approach that is pure data-driven, this study would present a proof of 
principle for using non-coding genotypes in cancer precision medicine. 
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1.1 REVIEW ON LNCRNA AND CANCER BIOLOGY 
1.1.1 Theory of carcinogenesis 
In the year 2000, Hanahan and Weinberg proposed the concept of cancer hallmarks, which forms 
the very fundamental principle of the transformation from normal cells to the malignant[7]. During 
the past decades, a remarkable progress towards the understanding of the cancer has expanded our 
knowledge to this disease. As a result, the number of cancer hallmarks are further expanded to ten, 
and this number keeps increasing along the accumulated studies in carcinogenesis and cancer 
therapies[8]. 
Tumor formation is a multistep process. To become tumorigenic, a normal cell need to 
acquire particular capacities and evolve progressively to a neoplastic stage. These basic but distinct 
hallmarks include:  
(1) Sustaining proliferative signaling; 
(2) Deregulating cellular energetics; 
(3) Resisting cell death;  
(4) Genome instability and mutations; 
(5) Inducing angiogenesis;  
(6) Enabling replicative immortality;  
(7) Activating invasion and metastasis;  
(8) Tumor-promoting inflammation; 
(9) Evading growth suppressors; 
(10) Avoiding immune destruction. 
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Drugs that could inhibit or interfere with these cancer hallmarks have been rapidly 
developed in past few years, and some of them have already been approved or in clinical trials as 
promising treatments for various types of human cancer. 
1.1.2 Definition of long non-coding RNAs (lncRNAs) 
Non-coding RNAs are transcripts that can not be translated into proteins. Those non-coding RNAs 
that are longer than 200 nucleotides are defined as lncRNAs[9]. According to their genomic 
location, lncRNAs are classified as stand-alone lncRNAs, natural antisense transcripts, long 
intergenic ncRNAs, divergent and promoter-associated transcripts, as well as pseudogenes[10]. 
Many studies have demonstrated that lncRNAs have an approximately 10-fold lower 
abundance than mRNAs in cell populations[11, 12]. This could be explained by the high 
expression variation of lncRNAs between individual cells. In case of the protein coding genes, this 
variation might be lower[13]. On the other hand, about 78% of the lncRNAs are found to be tissue-
specific. This percentage is much higher than that of mRNAs, which is around 20%. In general, 
lncRNAs are mostly located and transcribed in intergenic regions of the genome, but the majority 
of them are transcribed under very complex networks, which may overlap with both sense and 
antisense transcripts, and sometimes even cover part of the protein-coding genes[14]. 
Next generation sequencing studies indicated the huge amount of lncRNAs existing in 
eukaryotes and prokaryotes. However, despite the accumulation of evidences suggesting the 
functional roles of lncRNAs[15, 16], only a very small proportion of them has been clearly 
validated in experiments. By the end of the year 2017, according to the record of LncRNAWiki, 
only about ~1,000 human lncRNAs’ regulation function has been experimentally 
demonstrated[17]. 
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1.1.3 Mechanisms of action: regulation through lncRNAs 
Although lncRNAs do not encode protein, they can achieve their biological function by regulating 
the expression of other genes. There are growing number of evidences suggest that lncRNAs can 
employ one to several mechanisms of action that are described below[10]. 
LncRNAs in epigenetic regulation 
LncRNAs can recruit protein factors to regulate the chromatin states by either cis or trans-
action[18]. For example, studies have shown that HOTAIR can repress the transcription of HOXD 
in trans by interacting with PRC2, a chromatin-modifying complex[19]. In contrary, Xist, another 
well-known lncRNA, can recruit PRC2 in cis to the synthesis site and lead to the X chromosome 
inactivation[20]. 
In some cases, lncRNAs can also function as a scaffold on which different protein 
complexes can be assembled together. For instance, besides the interaction with PRC2, HOTAIR 
could also interact with the LSD1/CoREST/REST complex, which leads to the demethylation of 
histone H3K4 and hence repress the gene activation[21]. 
LncRNAs in transcriptional regulation 
LncRNAs could direct affect the transcription by decoying, co-regulating or inhibiting the 
RNA polymerase. For example, Gas5 could compete for the binding of transcription factor on 
glucocorticoid receptors, keeping away other glucocorticoid response elements[22]. SRA is an 
lncRNA coactivator of nuclear steroid receptors[23]. The co-activation mechanism via SRA could 
result in dramatic alterations of the downstream targets of these nuclear receptors[24]. Some 
lncRNAs transcribed from SINEs (a class of retrotransposons) may repress the transcript synthesis 
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by directly binding with RNA Pol II. The binding between these lncRNAs and RNA polymerase 
may prevent the formation of pre-initiation complexes that are essential to transcription[25, 26]. 
LncRNAs in post-transcriptional regulation 
In addition to the epigenetic and transcriptional regulation, lncRNAs could also participate 
in mRNA processing and stability regulation. As an example, MALAT1 could mediate the 
alternative splicing by interacting with the splicing factors[27]. On the other hand, transcripts in 
the cytoplasm could be regulated by factors that influence the RNA stability. More than 5% of 
human genes contain a set of AU-rich elements (AREs) in 3’-UTRs. This region could recruit 
RNA-binding proteins and lead to the destabilization of host transcripts[28]. Studies have found 
an antisense that is produced from the 3’-UTR of iNOS could interact with its sense counterpart 
and an ARE-binding factor. The interaction could contribute to the stability of transcripts that 
contain AREs[29]. 
LncRNAs in microRNA-mediated regulation 
Besides to the mechanisms introduced above, many studies have revealed that lncRNAs 
may interfere with mRNA destabilization mediated by microRNAs. A good example is BACE-AS 
(antisense transcript of the Alzheimer-associated β-secretase-1), which could increase mRNA 
stability of its sense counterpart through masking miR-485-5p binding sites[30, 31]. 
LncRNAs can also compete with microRNAs themselves in addition to competing with 
the binding sites. Some pseudogenes, such as PTENP1[32], have binding sites for microRNAs on 
3’-UTRs. These binding sites allow the pseudogenes to be sponges that could sequester the 
microRNAs away from their original targets.  
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LncRNAs can also be host genes for microRNAs. For instance, H19 is the host gene of 
miR-675[33]. The imprinted Gtl2, anti-Rtl1, and Mirg RNAs are also found to be microRNA host 
genes, which have covered approximately 50 microRNAs and 40 snoRNAs[34]. 
1.1.4 LncRNAs involved in cancer initiation and progression 
The association between lncRNAs and diseases have raised a growing interest, of which the most 
notable one is the cancer[35].  
LncRNAs can participate in the regulation of sustaining proliferative signaling. A recent 
study in prostate cancer discovered an lncRNA, PCAT-1, which promotes cell proliferation and is 
highly upregulated in some metastatic and high-grade localized prostate cancers[36].Several 
lncRNAs could also help tumor cells evading tumor growth suppressors. Researchers found ANRIL, 
an lncRNA that is highly expressed in several cancers, could directly interact with a subunit of 
PRC2 and recruits the complex to repress the expression of p15, a well-known tumor suppressor. 
They also found that the depletion of ANRIL could increase p15 expression and therefore inhibit 
the cell proliferation[37]. In addition, many studies revealed the regulation role of lncRNAs in 
activating invasion and metastasis. MALAT-1 is found to associate with metastasis and poor 
prognosis in early-stage non-small cell lung cancer[38]. This lncRNA is highly expressed in many 
human cells and is, interestingly, highly conserved across several species. Moreover, lncRNAs 
could also take part in preventing the tumor cells from cell death. PCGEM1 was identified as a 
prostate cancer-associated lncRNA that could potentially induce a delayed induction of p53 and 
p21 after being overexpressed[39].  
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Collectively, the above examples strongly emphasize the functional importance of 
lncRNAs in regulating the hallmarks of cancer, suggesting the great potential of lncRNAs to 
become robust diagnostic markers and therapeutic targets in cancer therapy. 
1.2 MULTI-DIMENSIONAL CANCER GENOMIC DATA SETS 
1.2.1 The Cancer Genome Atlas (TCGA) 
The Cancer Genome Atlas (TCGA) [40] is a dataset comprising 2.5 petabytes of multi-dimensional 
genomic and epigenetic data for more than 11,000 cancer patients across 33 cancer types. This 
publically available database has greatly facilitated the cancer research community for decades in 
understanding the cancer initiation, progression and therapeutics. 
On December 13, 2015, National Institutes of Health (NIH) launched the TCGA project to 
comprehensively explore the landscape of genomic alterations in human tumors. Since then, taking 
the advantage of the high-speed development of next generation sequencing techniques, scientists 
in TCGA research network have curated huge amount of data for patients involved in this project. 
These data include genomic data such as DNA-seq, RNA-seq, methylation, copy number 
alterations and SNPs, as well as clinical information such as survival, tumor residues, 
drug/immune response and other prognostic metrics. These data enabled both independent 
researchers and the TCGA research network to understand the association between individual or 
sets of genes and various cancer disease phenotypes. 
For example, the major type of ovarian cancer is the ovarian serous cystadenocarcinoma. 
Due to a lack of effective early detection and treatment, only 31% of patients are expected to live 
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for 5 years or more[41]. By performing in-depth analyses of the genomic and epigenetic alterations 
in high-grade ovarian serous cystadenocarcinoma, TCGA researchers successfully identified 
several druggable mutations with high presence in ovarian cancer patients. These mutations 
include TP53 mutation in 96% of the specimens, as well as BRCA1/2 mutated in 22% of the patient 
samples. In their study, they also successfully identified subtypes of ovarian cancer on different 
level, from the transcriptional to the transcriptional, that is associated with patient prognosis. 
Recent integrative studies using TCGA data have further demonstrate the effect of BRCA1/2 
mutations on ovarian cancer patients’ survival[42]. These studies on the TCGA ovarian cancer 
dataset have greatly expanded our knowledge about this fatal disease. 
1.2.2 Genomics of Drug Sensitivity in Cancer (GDSC) 
The GDSC database (www.cancerRxgene.org) is one of the largest open access resource for 
information on drug sensitivity and molecular markers of drug response in cancer cell lines. 
Currently, this database contains drug sensitivity data for approximately 75,000 experiments, 
covering the response profile of 256 anticancer drugs across more than 1,000 cancer cell lines. 
These 265 compounds include 48 clinical drugs, 76 drugs in clinical development and 141 
experimental compounds. 
One of the advantage of GDSC is that all of the cell line drug sensitivity data are integrated 
with large genomic datasets obtained from the Catalogue of Somatic Mutations in Cancer 
(COSMIC) [43]database. These genomic information includes information on somatic mutations 
in cancer genes, gene amplification and deletion, tissue type and transcriptional data. Connecting 
the genotypes with drug response phenotypes, the GDSC database have provided an unprecedented 
opportunity to facilitate the discovery of new biomarkers for cancer precision therapies. 
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1.2.3 Cancer Cell Lines Encyclopedia (CCLE) 
The Cancer Cell Line Encyclopedia (CCLE) [2] project is a compilation of gene expression, 
mutation and copy number alterations from 947 human cancer cell lines. Coupling with 
pharmacological profiles for 24 anticancer drugs across 479 of the cell lines, the CCLE database 
enabled the researchers to identify novel gene-expression-based predictors of drug resistance.  
Using multi-level pharmacogenomic information in CCLE, the researchers discovered a 
novel correlation between plasma cell lineage and IGF1 receptor inhibitors sensitivity. They also 
found a dramatic association between AHR expression and MEK inhibitor efficacy in NRAS-
mutant lines. These results, which came from the in silico analyses, were successfully validated in 
cell line experiments, indicating the great potential of CCLE in exploring novel therapeutic 
biomarkers in cancer drug development. 
1.3 MACHINE LEARNING FOR INTEGRATIVE OMICS DATA ANALYSIS 
1.3.1 Curse of dimensionality 
In quantitative research studies, ‘curse of dimensionality’, which was first introduced by Richard 
Bellman when he was solving optimization problems for a large-scale dataset in 1957, has always 
been an essential issue. In many computational problems (especially for optimization problems), 
when the dimension increases, the computing complexity would increase exponentially. Such 
increase would make these computing tasks unaccomplishable within life time, and the optimized 
solution is usually unachievable. 
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Besides the optimization problem, the high dimension also leads to another type of ‘curse’. 
In statistics, when estimating a kernel density function within given population, high dimensions 
would usually make the estimation function converge too slowly to approach the true solution. On 
the other hand, when applying hypothesis testing to high dimensional data, the resulting test 
statistics could be misleading for scientific interpretation. For example, in a real situation of 
genotype-phenotype association analysis where we have 20,000 genes, we would expect 20,000 * 
0.01 = 200 genes with p-value < 0.01 simply by chance. Such kind of false discovery will mask 
the true causal relationship, and will greatly increase the time and the cost for experimental and 
clinical validation. 
1.3.2 Strategies to reduce dimensions 
As more and more high-dimensional data are accumulated through modern techniques, the issue 
of ‘curse of dimensionality’ has gained growing attention. There are many widely used dimension 
reduction algorithms to reduce the redundant dimensions and thus facilitate large-scale data 
analysis. 
The most common and fundamental way to reduce dimension is principal component 
analysis (PCA) and singular value decomposition (SVD). These two technique would allow the 
high-dimensional data in Euclidean space to be projected to a low-dimensional orthogonal space. 
Features with similar sub-population structure will be very close to each other, giving us the 
information and the relationship among individual features in the original-dimension space. 
However, one drawback of these two algorithms is that, despite their efficiency in reducing the 
high-dimensional noise, they do not generate sparsity for the features. In other words, PCA and 
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SVD would not help identifying the features (e.g. genes, SNPs) that are relevant to the phenotypes 
(e.g. disease progression, survival).  
Another similar approach is clustering. However, instead of decomposing the variance 
structure as PCA and SVD did, the clustering algorithms will take the information of a predefined 
distance between individual features, and could provide prediction when a new feature comes in. 
Taken together, these techniques are called ‘unsupervised machine learning’, because they do not 
need any label information for training. In genomic studies, these label information usually refer 
to biological priori knowledge or disease phenotypes. Without the label information, unsupervised 
machine learning would purely focus on the data pattern. They can be hypothesis generating, but 
will also become challenging when the underlying statistical property of the data is hard to address. 
Therefore, to identify the phenotype/outcome-associated features, a class of algorithms, 
named ‘supervised machine learning’, is developed in contrast to ‘unsupervised machine learning’. 
In genomic studies, the goal of supervised machine learning is to construct a classification or a 
regression model from the given genomic data to predict the disease or phenotype information. 
Popular supervised machine learning classifiers used in genomic studies include random forest, 
Bayesian network, support vector machines as well as neural networks; in case of regression 
models, least absolute shrinkage and selection operator (LASSO) regression and Elastic Net (EN) 
regression are the most widely used approaches when number of features (p) are far greater than 
number of samples (n). With the label information being involved, these supervised machine 
learning algorithms could score each of the features in the original data space based on their 
contribution to the optimization problem or the prediction performance. Through simple ranking, 
regularization or resampling aggregation, sparsity could be generated and the most relevant 
features to prediction outcome could be easily identified. 
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1.3.3 Regularization in regression setting 
In common genomic applications, we would usually have ten thousands of genes but only hundreds 
of samples. This situation is called ‘small n, large p’, where the least square (LS) linear models 
could not fit the models well because the parameters are not identifiable in the below optimization 
problem: 
?̂?𝐿𝑆 = 𝑎𝑟𝑔 min
𝛽
∑ (𝑦𝑖 − 𝛽0 − ∑ 𝛽𝑗𝑋𝑖𝑗
𝑝
𝑗=1 )
2𝑛
𝑖 . 
In the past few decades, regularization methods are developed to practically solve this 
problem without exhaustively searching all possible feature combinations. The most fundamental 
regularization methods are Ridge regression and Lasso regression. 
Ridge regression 
Ridge regression was first proposed by Andrey Tikhonov in 1995. The optimization 
problem of Ridge regression takes the form: 
?̂?𝑅𝑖𝑑𝑔𝑒 = 𝑎𝑟𝑔 min
𝛽
∑ (𝑦𝑖 − 𝛽0 − ∑ 𝛽𝑗𝑋𝑖𝑗
𝑝
𝑗=1
)
2
𝑛
𝑖
+ 𝜆‖𝛽‖𝐿2
2 . 
The solution of the optimization problem could be derived by partial deviation on 𝛽: 
?̂?𝑅𝑖𝑑𝑔𝑒 = (𝑋𝑇𝑋 + 𝜆𝐼 )−1𝑋𝑇𝑦 
The term 𝜆𝐼 makes the problem nonsingular, and hence allows the optimization function 
to achieve a unique solution. To decide an appropriate 𝜆, cross-validation is usually utilized during 
parameter optimization. Notably, since ?̂?𝑅𝑖𝑑𝑔𝑒 is not invariant, standardization must be applied 
before fitting the model. 
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Since the Ridge penalty takes the form of L2-norm, which is a smooth function, it is hard 
to provide sparsity to the features. In other words, although Ridge regression could provide a 
solution to the linear regression equation, it may sometimes overfit the model with a great number 
of features that have coefficients extremely close to zero. 
Lasso regression 
In contrast to Ridge regression, Lasso regression takes the L1-norm penalty, which is not 
a smooth function and hence is much easier to generate sparsity. 
The Lasso regression was introduced by Robert Tibshirani in 1996. The optimization 
problem of Lasso regression takes the form: 
?̂?𝐿𝑎𝑠𝑠𝑜 = 𝑎𝑟𝑔 min
𝛽
∑ (𝑦𝑖 − 𝛽0 − ∑ 𝛽𝑗𝑋𝑖𝑗
𝑝
𝑗=1
)
2
𝑛
𝑖
+ 𝜆‖𝛽‖𝐿1. 
Since the shape of L1-norm is sharp while L2-norm is smooth, the optimization contour of 
Lasso is more likely to hit the vertex of constrain region compared to Ridge regression. Therefore, 
under the setting of Lasso regression, coefficients of features that do not have enough contribution 
to the model performance will be pulled to zeros. This unique feature of Lasso makes it an ideal 
algorithm to select features in genomic studies, where the number of genes is usually far greater 
than number of samples. Although Lasso could be a biased estimator, it has a much lower variance 
in predicting the test sets because less features are kept in a model. Therefore, Lasso is also an 
ideal approach to reduce the risk of overfitting in large-scale data analysis. 
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1.3.4 Feature selection through Elastic Net 
When solving optimization problem under situation of ‘small n, large p’, collinearity between 
individual features is not ignorable. In previous section, we have shown that Ridge regression 
makes all coefficients non-zero (hence no sparsity is provided), while Lasso forces some of the 
coefficients to zero. Therefore, when there is a group of covariates that are highly correlated with 
each other, Lasso will randomly include one of them into the final model. This is a drawback of 
Lasso regression, since the procedure of randomly picking could be extremely uninterpretable. 
To overcome this problem, Elastic Net regression, which combines the Ridge and Lasso 
penalty together in the optimization function, was proposed. The optimization formula of Elastic 
Net is shown below: 
𝑚𝑖𝑛
(𝛽0,𝛽)∈𝑅𝑝+1
𝑅𝑒𝑔𝜆(𝛽0, 𝛽) = 𝑚𝑖𝑛
(𝛽0,𝛽)∈𝑅𝑝+1
[
1
2𝑁
∑ (𝑦𝑖 − 𝛽0 − 𝑥𝑖
𝛵,∙ 𝛽)2 + 𝜆𝑃𝛼(𝛽)
𝑁
𝑖=1 ], 
where 
𝑃𝛼(𝛽) = (1 − 𝛼)
1
2
‖𝛽‖𝐿2
2 + 𝛼‖𝛽‖𝐿1 . 
The parameters 𝜆, 𝛼 control the total weight of two penalties and the relative proportion 
between them. When there is high collinearity among a group of features, Elastic Net will retain 
the entire group in the final model (more Ridge). Meanwhile, Elastic Net will still keep the sparsity 
for the other features (more Lasso). As a result, the flexibility of Elastic Net allows it to alleviate 
the shortcomings of both Ridge and Lasso regression, and hence perform better in many cases. 
In this study, I chose Elastic Net regression as the core algorithm to identify drug-response-
related lncRNAs based on three reasons. First, this study encounters a very typical case of ‘small 
n, large p’: there are more than 10,000 lncRNAs, but only about 500 cancer cell lines are available 
for model training. Second, a nature of gene expression is its high collinearity between individual 
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genes. Such collinearity may imply a biological function within a group of highly-correlated genes, 
thus, I would prefer to retain this kind of sub-structures in constructing the identification models. 
Another reason of choosing Elastic Net regression is that, before this study, many high-profile 
projects have demonstrated the power of this regression algorithm in identifying critical genomic 
features that could predict drug response in cancer cell lines[2]. Taken these reasons together, I 
would use Elastic Net regression in this study to (1) identify potential drug response regulator 
lncRNAs as well as (2) to predict drug response in cancer patients. 
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2.0  METHODOLOGY 
In this chapter, methods used throughout this thesis will be divided into four sections. The first 
section ‘Data Profiling and Preprocessing’ will include the strategies and details in profiling the 
multi-dimensional high-throughput data used in this study, i.e. pharmacological data for anti-
cancer agents, as well as genomic landscape of cancer cell lines and patient samples. The second 
section ‘Modelling the Drug Response via Machine Learning’ will describe the training and 
construction procedures of lncRNA-based Elastic Net regression Prediction (LENP) models. The 
third section ‘Prediction and Functional Analysis’ will describe the methodologies and algorithms 
that are used to explore lncRNAs’ mechanism in regulating cancer drug resistance. The fourth 
section ‘Experimental Validation’ will include the RNA-seq analysis and in vitro experiment 
details in validating a potential drug-resistance regulator lncRNA in breast cancer cell lines. 
2.1 DATA PROFILING AND PREPROCESSING 
2.1.1 Pre-processing the lncRNAs alteration data 
For cancer cell lines, expression of 13,335 lncRNAs across 505 cancer cell lines from Cancer Cell 
Line Encyclopedia (CCLE) was downloaded from Expression Atlas [44] with matched drug 
response data from Genomics of Drug Sensitivity in Cancer (GDSC). For patient samples, 
expression of 12,190 cancer-related lncRNAs in 5,605 TCGA patient samples was downloaded 
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from MiTranscriptome[45]. Expression level of these lncRNAs are logarithmic transformed and 
z-score normalized for both cell lines and patients. 
We obtained the lncRNAs copy number alteration data for both 505 cell lines and 5,605 
TCGA patient samples by mapping 12,139 Affymetrix SNP 6.0 microarray segmentations to 2,614 
lncRNA regions. 
For DNA methylation, we repurposed IIlumina 450K Human Methylation microarray to 
get beta values of 2,804 unique probes for lncRNAs in (i) 1,028 cell lines from COSMIC[43] and 
(ii) 5,605 patients from TCGA. 
2.1.2 Pre-processing of drug response data 
Drug response data of 265 compounds across 1,001 cancer cell lines were downloaded from GDSC 
database[43]. These 265 compounds include 48 clinical drugs, 76 drugs in clinical development 
and 141 experimental compounds. The drug response in each cell line is indicated by logarithmic 
transformed IC50s and AUCs. 505 cell lines with genomic alteration data available are retained 
for model training and following analysis. 
2.1.3 Compare the lncRNAs alterations between cell lines and primary tumors 
The comparison between cell lines and tumors was based on feature correlations and an adjusted 
K-nearest-neighbor matching with the average, broken down by different cancer types. 
A bootstrapping procedure was performed for each comparison: for each cancer type, we 
calculate the fold-change for each genomic feature (e.g. gene expression, methylation, copy 
number alterations) between that cancer type and a resampling of all other cancer types. To ensure 
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the representation of homogeneous tissue-type, we only retained cancer types with primary tumor 
samples more than 15 and cell line samples more than 20. Next, we calculated the pairwise 
Pearson's correlation coefficient of the fold-changes between cell lines and primary tumors. This 
procedure would be iterated for 10 times with different samplings. The final asymmetric 
correlation matrix for each genomic feature is an average matrix of coefficients obtained by 10 
iterations, and the diagonal demonstrated the agreement between cell lines and tumors within the 
same cancer type. A comparison with p-value fell into the first 10% percentile would be considered 
as significant correlation. This correlation matrix was further used to fit the nearest-neighbor 
classification model implementing by ball tree algorithm. 
2.2 MODELLING THE DRUG RESPONSE VIA MACHINE LEARNING 
2.2.1 Identification of predictive lncRNA-drug interactions 
To identify lncRNAs that were most associated with drug response, we applied Elastic Net 
regression[46], a machine learning approach, combined with a bootstrapping procedure for each 
of the 265 compounds. For each compound, this algorithm would pick up group of lncRNAs whose 
expression pattern could best explain the drug sensitivity profiles of the cell lines. The Elastic Net 
regression is a well-demonstrated model to work with the conditions in which the number of 
features is far greater than the number of observations. Before our study, many high-profile studies 
have already applied this regression algorithm to identify critical genomic features that could 
predict drug response in cancer cell lines[43]. 
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For each compound, we constructed a drug response vector 𝑌 ∈ 𝑅𝑁,1 , where 𝑁  is the 
number of cell lines treated with this compound. The values in the vector represent the drug 
responses across these cell lines, i.e. logarithmic transformed IC50 or area under the curve (AUC). 
For these cell lines, we then constructed an lncRNA expression matrix 𝑋 ∈ 𝐸𝑁,𝑝, where 𝑁 is the 
number of cell lines and 𝑝 is the number of lncRNAs. With input of 𝑌 and 𝑋, we then used the 
scikit-learn 0.17.0 package to solve the following optimization problem:  
𝑚𝑖𝑛
(𝛽0,𝛽)∈𝑅𝑝+1
𝑅𝑒𝑔𝜆(𝛽0, 𝛽) = 𝑚𝑖𝑛
(𝛽0,𝛽)∈𝑅𝑝+1
[
1
2𝑁
∑(𝑦𝑖 − 𝛽0 − 𝑥𝑖
𝛵,∙ 𝛽)2 + 𝜆𝑃𝛼(𝛽)
𝑁
𝑖=1
], 
where 
𝑃𝛼(𝛽) = (1 − 𝛼)
1
2
‖𝛽‖𝐿2
2 + 𝛼‖𝛽‖𝐿1 . 
In this equation, 𝛼 controls the ratio of the 𝐿1 and 𝐿2 penalty terms, while 𝜆 controls the 
overall weight of the regression penalty. The optimization begins with 10 values of 𝛼 ∈ [0.2,1.0] 
and 200 values of 𝜆 = 𝑒𝜏 with 𝜏 ∈ [−5,5]. The optimal 𝛼 and 𝜆 that lead to the minimal mean 
square error of the regression model is obtained by 10-fold cross-validation. 
Next, we implemented a bootstrapping strategy to identify the most predictive lncRNAs 
for each compound. This procedure would generate 200 resampled datasets with replacement from 
the complete sample sets, (𝑋𝐵𝑆𝑖 , 𝑌𝐵𝑆𝑖)𝑖=1,2,…,200, where 𝑋
𝐵𝑆𝑖 ∈ 𝐸𝑁,𝑝 and𝑌𝐵𝑆𝑖 ∈ 𝑅𝑁,1. Based on the 
optimal 𝛼 and 𝜆, the elastic net equation would be solved for each of the resampled datasets, and 
a regression coefficient matrix 𝛽𝐵𝑆 ∈ 𝐵𝑝,200 would finally be built for each compound.  
To assess the extent to which an lncRNA is associated with the drug response, we then 
created a metric named ‘predictive score’ based on how frequent this lncRNA is selected by the 
regression model during the bootstrapping. For each lncRNA 𝑢 of each compound,𝑢 ∈ {1,2, … , 𝑝}, 
the predictive score of lncRNA 𝑢 is then calculated by: 
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𝑃𝑆𝑢 =
1
200
∑ 𝐼(𝛽𝑢,𝑗
𝐵𝑆)200𝑗=1 , where 𝐼(𝑥) = {
0, 𝑥 = 0
1, 𝑥 ≠ 0
. 
We then define an lncRNA as predictive to one compound if its predictive score is higher 
than 0.1. If an lncRNA has a predictive score higher than 0.8, we would regard it as a strong 
predictor to that compound. LncRNAs with predictive score higher than 0.1, together with the 
corresponding compounds, will be termed as candidate lncRNA-drug interactions and are retained 
for the following analyses. 
2.2.2 Pairwise comparison of feature selection 
To compare the similarity of predictive lncRNA sets between compounds, we used three different 
measurements to perform the pairwise comparison: Fisher’s exact test, Cohen’s Kappa score and 
Tanimoto distance. For lncRNA set of each compound 𝑑 (𝑑 ∈ {1,2, … ,265}), we dichotomized 
their predictive scores to 0 and 1 based on whether an lncRNA is considered as predictive or not. 
This operation would generate a binary vector 𝐵𝑑
𝑝,1
 for each compound 𝑑, where 𝑝 is the number 
of lncRNAs. Next, a similarity score matrix would be built based on the pairwise comparison of 
(𝐵𝑑
𝑝,1)
𝑑∈{1,2,…,265}
 by performing Fisher’s exact test, Cohen’s Kappa score or Tanimoto distance. 
The resulting matrix would then be analyzed by hierarchical clustering using ‘average’ method 
and Euclidean distance. 
2.2.3 Lineage effect on drug response and lncRNA expression 
ANOVA are used to evaluate the contribution of lineages to the drug response. For ANOVA, the 
cell lines are grouped by cancer types, following by the comparison between the inter- and intra-
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type variance of drug responses for each compound. A significant p-value indicates that the 
response of that drug is likely to be cancer-specific. 
2.2.4 Construction of LncRNA-based EN regression Prediction (LENP) models 
For each of the 265 compounds, we selected top 20 lncRNAs with highest predictive score to build 
predictive models of drug response with Elastic Net regression. For each compound, we 
constructed a drug response vector 𝑌 ∈ 𝑅𝑁,1, where 𝑁 is the number of cell lines treated with this 
compound. The values in the vector represent the drug responses across these cell lines, i.e. 
logarithmic transformed IC50 or area under the curve (AUC). For these cell lines, we then 
constructed an lncRNA expression matrix 𝑋 ∈ 𝐸𝑁,20, where 𝑁 is the number of cell lines. With 
input of 𝑌 and 𝑋, we optimize the parameters with 10 values of 𝛼 ∈ [0.2,1.0] and 200 values of 
𝜆 = 𝑒𝜏 with 𝜏 ∈ [−5,5] by 10-fold cross-validation. Using optimal parameters, we build the final 
model 𝑌 = 𝑓(𝑋) for each compound and estimate the predictive power by 10 iterations of 10-fold 
cross validation. The assessment is achieved by calculating the Pearson’s correlation coefficient 
and Kendall’s 𝜏 between the predicted and observed drug activity. We selected the best models 
based on the cross validation process. 
2.2.5 Independent validation of LENP model performance 
To assess the robustness of our pan-cancer as well as cancer-specific models, we obtained drug 
response data in the Cancer Cell Line Encyclopedia (CCLE) [2] from the CCLE web-portal. After 
mapping the cell lines and compounds to those in our study, we got 389 overlapping cell lines and 
15 overlapping compounds. Since AUC values were not available for the CCLE datasets, we only 
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focused on predicting the IC50s using our models. The prediction performance is evaluated by the 
Pearson’s correlation between predicted and real IC50s in CCLE study. 
2.3 PREDICTION AND FUNCTIONAL ANALYSIS 
2.3.1 Predict the drug response in patient samples 
Expression of 2,614 cancer-related lncRNAs in 3,814 TCGA patients with survival information 
available and was obtained from MiTranscriptome[45]. Patients with stage-1 disease are further 
filtered out except for the LAML patients. Using the expression data, we constructed an expression 
matrix 𝐸 ∈ 𝑅𝑁,𝑝 , where 𝑁  is the number of patients and 𝑝  is the number of lncRNAs. For 
compound 𝑖 , the predicted response 𝑃𝑖 ∈ 𝑅
𝑁,1 is calculated by the model based on lncRNA 
expression 𝑒𝑁,20 ∈ 𝐸
𝑁,𝑝, forming a final matrix of predicted response𝑃 ∈ 𝑅𝑁,265. The predicted 
response is then sorted by values, from which patients of first quantile are labeled as ‘sensitive 
response’. The patients are then categorized by 𝑐cancer types, where ∑ 𝐶𝑗 = 𝑁
𝑐
𝑗=1 . The sensitive 
percentage 𝑆𝑗,𝑖
𝑝𝑒𝑟𝑐𝑒𝑛𝑡
for compound 𝑖 is calculated by 
𝑛
𝐶𝑗
, where 𝑛 is the number of patients that have 
‘sensitive response’ in cancer 𝑗 . Finally, a matrix of sensitive percentage 𝑆𝑗,265
𝑝𝑒𝑟𝑐𝑒𝑛𝑡
for all the 
compounds is constructed based on these results. 
2.3.2 Survival analysis 
Univariate Cox regression. Survival information of TCGA patients, including overall survival (OS) 
and progression-free interval (PFI), was obtained from TCGA database. Cox regression based on 
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predicted drug response 𝑃 ∈ 𝑅𝑁,𝑖 was then applied for each compound 𝑖, where 𝑖 ∈ {1,2, … ,265}. 
The regression algorithm is implemented by Lifelines 0.8.0.1 package. The hazard ratios are 
calculated by exponentiation of the coefficients from the regression models. 
Multivariate Cox regression. Clinical information about TCGA patients, including age and 
disease stages at diagnosis, was obtained from TCGA database. For each patient, the age is 
dichotomized as ‘young’ and ‘old’ with a cutoff at 65 years’ old. For patients from cancer 𝑐, the 
predicted response of 𝑛 drugs that are approved for this cancer would be assigned ranks based on 
predicted response values. The weighted average 𝑅 ´ of the ranks for each patient is given as follow: 
?´? =
∑ 𝑤𝑖𝑅𝑖
𝑛
𝑖=1
∑ 𝑤𝑖
𝑛
𝑖=1
, where 𝑤𝑖 = {
1.0, 𝑖 ∈ {1𝑠𝑡𝑙𝑖𝑛𝑒𝑎𝑔𝑒𝑛𝑡𝑠}
0.5, 𝑖 ∈ {2𝑛𝑑𝑙𝑖𝑛𝑒𝑎𝑔𝑒𝑛𝑡𝑠}
. 
Next, Kaplan-Meier analysis was performed based on the weighted average ranks and 
overall survival (OS) and progression free interval (PFI). After that, the weighted average ranks 
are sorted by ascending and dichotomized as ‘sensitive response’ (top 30%), ‘partial response’ 
(30%~50%), ‘partial resistance’ (50%~70%), and ‘resistance’ (bottom 30%). With the survival 
information and the input factors (age, disease stage and weighted average rank of the predicted 
response), a multivariate Cox regression is then performed for each cancer type. The hazard ratios 
for each of the factors are calculated by exponentiation of the coefficients from the regression 
models. 
2.3.3 Identification of multi-drug-response (MDR) related lncRNAs 
To identify MDR-related lncRNAs that are independent from drug mechanism, we constructed a 
vector 𝐷 with length 𝑚 for each predictive lncRNA 𝑖. Each element 𝐷𝑗  in 𝐷 denotes the target 
pathway of the corresponding agent 𝑗 that lncRNA 𝑖 is predictive to, and 𝑗 ∈ {1,2, … , 𝑚}. In total, 
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𝐷  will be expected to have 𝑛  unique elements, denoted by 𝐶 . Next, for each lncRNA 𝑖 , we 
calculate the Shannon entropy 𝐻𝑖of 𝐷 using the following formula: 
𝐻𝑖(𝐷) = − ∑ 𝑝𝐶𝑘𝑙𝑜𝑔2𝑝𝐶𝑘
𝑛
𝑘=0 , where 𝑝𝐶𝑘 = 𝑃𝑟(𝐷𝑗 = 𝐶𝑘 𝑗∈{1,2,…,𝑚}). 
The resulted entropy metrics will be further transformed into z scores. LncRNAs with a z 
score greater than 1, i.e. one standard deviation from the right side of the mean, would be selected 
as an MDR-related lncRNA. 
2.3.4 Co-expression and Gene Sets Enrichment Analysis (GSEA) 
We calculated the Pearson’s correlation coefficients between 19,680 protein coding genes’ 
expression and 2,614 lncRNAs’ expression, forming a coefficient matrix  𝛽𝑝,𝑙 , where  𝑝 is the 
number of protein coding genes and𝑙 is the number of lncRNAs. We ranked the protein coding 
genes based on their expression correlation with lncRNAs. Gene Sets Enrichment Analysis (GSEA) 
is performed based on cancer hallmarks (h) genesets from GSEA database[47, 48]. The final 
enrichment score matrix is given by normalized enrichment score (NES) and false discovery rate 
(FDR) from GSEA. An enrichment with FDR <= 0.25 would be considered as significant 
enrichment.  
For each target pathway, we construct an lncRNA selection matrix by using top predictive 
lncRNAs from respective agents. Top predictive lncRNAs are defined as top 20 lncRNAs with 
highest predictive scores in single agent. An lncRNA selection vector is constructed for each 
compound, and is merged into a selection-pathway matrix with 21 rows (pathways) and 1,292 
columns (predictive lncRNAs that are top predictors for at least one compound). Next, one-sided 
(greater) Fisher’s exact test is performed to assess the enrichment of top lncRNAs in each pathway 
is assessed by based on dichotomized enrichment matrix and lncRNA selection matrix. 
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2.4 EXPERIMENTAL VALIDATION 
2.4.1 Cell culture, RNA interference and real-time PCR 
Human breast cancer cell lines, Hs578T and MCF-7, were purchased from American Type Culture 
Collection (ATCC) and cultured as suggested by ATCC’s guidelines. Human ovarian cancer cell 
line, A2780 and the cisplatin resistant version of the cell line, A2780cis, were obtained from the 
European Collection of Cell Cultures (ECACC), supplied by Sigma-Aldrich, and cultured in RPMI 
1640 medium supplemented with 2 mM glutamine, 10% FBS, 1% penicillin, and 1% streptomycin; 
A2780cis cells were also supplemented with 1 µM cisplatin. 
For RNA interference, cells were transfected with 40 nM siRNA targeting EPIC1, or 
control siRNA using Lipofectamine RNAiMAX (ThermoFisher, #13778150) per the 
manufacturer’s instructions. Total RNA was isolated 72 h later using an RNeasy Mini kit (Qiagen, 
#74104) according to the manufacturer’s instructions. For real-time PCR analysis, cDNAs were 
synthesized from 0.5 µg of total RNA using a High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, #4368813). Real-time PCR was performed with Power SYBR Green PCR 
Master Mix (Applied Biosystems, #4367659) on a QuantStudio 6 Flex Real-Time PCR System 
(Applied Biosystems). Relative gene expression was determined by ΔΔCt normalized to GAPDH.  
The following siRNAs were used (sense, antisense): EPIC1 siRNA_A#, 
CCUUCAGACUGUCUUUGAAdTdT, UUCAAAGACAGUCUGAAGGdTdT; EPIC1 
siRNA_B#, AGUGUGGCCUCAGCUGAAAdTdT, UUUCAGCUGAGGCCACACUdTdT; 
control siRNA, GUGCGUUGUUAGUACUAAUdTdT, AUUAGUACUAACAACGCACdTdT. 
Sequences of primers for qRT-PCR were: EPIC1 forward, TATCCCTCAGAGCTCCTGCT, and 
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EPIC1 reverse, AGGCTGGCAAGTGTGAATCT; GAPDH forward, 
GGTGAAGGTCGGAGTCAACG, and GAPDH reverse, TGGGTGGAATCATATTGGAACA. 
2.4.2 Validation of lncRNA-drug interactions in cell lines 
MCF-7 cells stably expressing an empty vector and EPIC1 (MCF-7/Vector and MCF-7/EPIC1) 
were established with retroviral particles. To validate lncRNA-Drug interactions, MCF-7/Vector 
and MCF-7/EPIC1 cells were seeded at 2,000 cells per well in 96-well culture plates and incubate 
for overnight at 37°C, 5 % CO2. After treatment with a series of 2-fold diluted drugs (JQ-1 and I-
BET-762) for 48 hours, MTT assays were performed with a CellTiter 96 Non-Radioactive Cell 
Proliferation Assay Kit (Promega, #G410) following the manufacture’s guidelines. The 
absorbance value was measured at 570 nm using an xMark Microplate Spectrophotometer (Bio-
Rad) with a reference wavelength of 630 nm and the IC50 of JQ-1 and I-BET-762 on cells was 
calculated, respectively. 
2.4.3 Next generation sequencing: RNA-seq analysis 
STAR-RSEM pipeline was used to profile and quantify the RNA-seq data of EPIC1-knockdown 
cell lines. Differential expression analysis and Gene Sets Enrichment Analysis were implemented 
as down-stream analyses for quantified expression data. 
 27 
3.0  RESULTS 
3.1 CELL LINES RECAPITULATE LNCRNA ALTERATIONS IN TUMORS 
3.1.1 Overview of lncRNA alteration profile in 27 cancer types 
To assess whether cancer cell lines resemble the primary tumors in the perspective of lncRNA 
alterations,  RNA-seq, copy number and DNA methylation data are obtained for 5,605 TCGA 
tumor samples and 505 cancer cell lines across 27 cancer types (Figure 1A, 1B and 1C).  
 
Figure 1 Genomic and epigenetic alterations of cancer-related lncRNAs in 505 cancer cell lines 
Cell lines are arranged by columns. LncRNAs are arranged by rows. Three heatmaps indicate the patterns of the expression 
(A), DNA methylation (B), and copy number (C) for cancer-related lncRNA (Online Methods). Twenty-two cancer types 
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are indicated by different colors on top of each heatmap. (D) Percentage of lncRNA genomic and epigenetic alterations 
occurring in at least one or at least three cell lines. 
The 2,614 cancer-related lncRNAs were first identified based on differential expression 
between patient tumors and normal tissues in the TCGA database. Among these cancer-related 
lncRNAs, all of them are expressed in at least one cancer cell line; 2,511 (96.06%) are expressed 
in at least three cell lines (Figure 1D).  
3.1.2 Correlation of lncRNA alterations between cell lines and primary tumors 
Using a pairwise correlation analysis with resampling procedure, the lncRNA expression 
profile in cell lines are shown to significantly correlate with patient tumors for 14 out of 18 
(77.78%) cancer types (Figure 2A). The DNA methylation profile in cell lines are highly 
correlated with tumors for 15 out of 19 (78.94%) cancer types (Figure 2B). In case of copy number 
alterations, 13 out of 18 (72.22%) cancer types exhibit significant correlation between primary 
tumors and cell lines (Figure 2C).  
The correlation coefficient reached to a median of 0.23 for expression (median p = 8.53 x 
10-17, Pearson's correlation) with random expectation at –0.03. For copy number alteration and 
DNA methylation, the correlation coefficient reached to medians of 0.49 (median p = 8.78 x 10-
93, Pearson's correlation) and 0.27 (median p = 1.32 x 10-18, Pearson's correlation), respectively 
(Figure 2A, 2B and 2C). 
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Figure 2 Pairwise Pearson's correlation of lncRNA alterations between cell lines and patient tumors 
Pairwise Pearson's correlation of lncRNA alterations between cell lines and patient tumors for each cancer-type in CNV, 
methylation and expression.  The correlation of lncRNA alteration within the same and different cancer types are shown in 
the boxplots. 
3.1.3 Represent the cancer types using lncRNA-based nearest-neighbor classifier 
To further determine if lncRNA alteration profiles in cancer cell lines are representative for patient 
tumor, we used a simple nearest-neighbor classifier based on the lncRNA alterations in patient 
tumors to predict the cancer type of cancer cell lines (Figure 3).  
Within the third nearest neighbors, the KNN classifier could correctly match the tissue of 
origin of cell lines to primary tumors using lncRNA methylation or copy number for 42.1% and 
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33.3% of the cases with random expectation at 15.7% and 11.1%, respectively. When using 
expression, the match rate increased to 50% with random expectation at 5.6%. When considering 
the fifth nearest neighbors, this percentage substantially increased to 73.6%, 55.5% and 83.3% 
(with random expectation at 21.1%, 22.2% and 16.7%) for methylation, copy number and 
expression.  
 
Figure 3 Nearest-neighbor classifier to predict cell origin 
Performance of a K-nearest-neighbor classifier to predict cell origin using CNV, methylation and expression respectively. 
In sum, the concordance of lncRNA alterations between primary tumors and cancer cell 
lines was most prominent in the expression level, followed by DNA methylation level and copy 
number level. Therefore, the following modelling and analyses sections would mostly focus on 
the expression profile of lncRNAs in cancer cell lines and patient samples. 
3.1.4 Discussion 
In this chapter, correlation analysis and classification algorithms were used to assess how lncRNAs 
alterations in primary tumors could be recapitulated by cancer cell lines. The results served as the 
very fundamental of using cell line-based panels to predict drug response in patient. 
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 In the following chapters, only the lncRNA expression profiles are included to train the 
EN-models, because (1) the lncRNA expression exhibits the highest similarity between cancer cell 
lines and patient tumors; (2) the changes of both CNA and DNA methylation will eventually be 
manifested by the expression of lncRNA, and (3) the redundancy of including lncRNA CNA and 
DNA methylation data may not be properly handled by the EN-model in current study. Emerging 
deep learning algorithms, such as artificial neural networks, have shed to light to modeling high-
dimension and high-redundancy data. In future study, we will use deep-learning algorithm to 
comprehensively model the cancer drug response by integrating lncRNA and PCG genomics and 
epigenetic changes.  
 
3.2 A LANDSCAPE OF LNCRNA-DRUG INTERACTIONS IN CANCER 
3.2.1 Overview of anti-cancer agents included in this study 
Drug response data of 265 compounds across 1,001 cancer cell lines were downloaded from GDSC 
database[43]. These 265 compounds, targeting 21 key pathways in cancer, include 48 clinical 
drugs, 76 drugs in clinical development and 141 experimental compounds. The drug response data 
includes the values of IC50 and area under the curve (AUC) of 265 anti-cancer agents from the 
GDSC database. 
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3.2.2 Identify lncRNA-drug interactions by Elastic Net regression 
LncRNAs expression profile and drug response data across 505 cancer cell lines were integrated 
to identify predictive lncRNA-drug interactions. Below shows the identification-prediction 
framework of this study (Figure 4).  
 
Figure 4 A flow chart of building lncRNA-based EN models. 
By conjugating Elastic Net (EN) Regression and bootstrap aggregating, lncRNA-drug 
response prediction models are built for each agent across all the cell lines (pan-cancer model) or 
cell lines from a specific cancer type (cancer-specific model). The model performance was 
assessed by the Pearson Correlation Coefficient between the predicted response and the observed 
response for each agent. Overall, pan-cancer models for 265 drugs achieved median performance 
at r = 0.31 (p = 6.76×10-5, Pearson’s correlation) in bootstrapping. Cancer-specific models built by 
smaller numbers of samples, on the other hand, achieved a decreased median performance at r = 
0.13 (Pearson’s correlation) (Figure 5A). 
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Figure 5 The Landscape of LncRNA-Drug Interactions in Cancer Cell Lines 
(A) Volcano plot of pan-cancer models (left) and cancer-specific models (right) performance in drug response prediction in 
the bootstrapping process. The negative log-transformed p values (y axis) and Pearson correlation coefficients (x axis) of 
each model were generated between predicted drug response and observed drug response.  
(B) A Venn diagram of the identified lncRNA-drug interactions the pan-cancer model and cancer-specific models. An 
interaction with predictive score higher than 0.8 is defined as strong interaction. 
(C) lncRNA-drug interactions landscape across 265 agents and 505 cancer cell lines. The predictive score for each lncRNA-
drug interaction and the negative log-transformed p value for Pearson's correlation between the lncRNA expression and IC50 
were shown in the y-axis and x-axis of the volcano plot.  
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To determine each lncRNA’s contribution to drug response, a predictive score (PS) was 
assigned to each lncRNA based on the frequency it was selected by EN regression throughout the 
bootstrapping. The lncRNA with higher PS would be more associated to the corresponding agent 
response, referring to a predictive lncRNA-drug interaction.  
Using IC50 as an indicator of drug response, this feature selection process identified 75,132 
lncRNA-drug interactions in pan-cancer models and 103,155 interactions in cancer-specific 
models (162,327 unique lncRNA-drug interactions in total) (Figure 5B and 5C). When using 
AUC as an indicator of drug response, a highly consistent lncRNA-drug interaction network was 
obtained (r = 0.63, p < 10-26, Pearson’s correlation), suggesting the robustness of our strategy.  
The EN regression successfully identified well-documented lncRNAs that are related to 
drug response. For instance, MEG3 overexpression is identified as a predictor of cisplatin 
sensitivity (PS: 0.15), which is consistent with previous findings that lung and ovarian cancer 
patients with MEG3 over-expression have better response to cisplatin treatment[49-51]. Our model 
also identified previously reported regulation of cisplatin response by HOTAIR [52], MALAT1 
[53] and NEAT1 [54]. Besides, we also uncovered novel interactions that potentially contribute to 
clinical outcome. For example, the expression of LINC00992 in primary tumors increases along 
with the disease progression (Figure 6A) and associates with poor patient survivals in multiple 
cancer types that routinely receive chemotherapy (Figure 6B). Meanwhile, LINC00992 is 
identified as a drug-resistance predictor for many cytotoxic agents, including cisplatin in the pan-
cancer model (PS: 0.99), gemcitabine in both pan-cancer (PS: 0.99) and BRCA models (PS: 0.22). 
LINC00992 overexpression related chemo-resistance may account for the observed poor prognosis 
in patients with high LINC0992 expression. 
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Figure 6 LINC00992 expression and correlation with survival 
(A) LINC00992 expression of TCGA cancer patients at different stages. (B) Kaplan-Meier plot of overall survival of patients 
with different LINC00992 expressions in breast cancer (left) and colon adenocarcinoma and rectum adenocarcinoma 
(right).    
3.2.3 Compare predictive lncRNAs between agents and target pathways 
Notably, one lncRNA could be predictive to multiple agents’ response, and agents targeting the 
same pathway tended to share similar predictive lncRNAs (Figure 7A).  
The below example shows that agents targeting the genome integrity shared significantly 
more predictive lncRNAs (p = 9.6×10-9, Wilcoxon Rank-Sum test) (Figure 7B). Moreover, within 
the genome integrity group, PARP inhibitors olaparib and talazoparib shared a significantly higher 
proportion of predictive lncRNAs (p = 1.6×10-55, Fisher's exact test) than with CHEK inhibitor 
AZD7762 (p = 8.9×10-6, Fisher’s exact test).  
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Figure 7 Similarity between predictive lncRNA selected by different agents. 
(A) Cumulative distribution of two-tailed Fisher’s exact test p-value shows the similarity between predictive 
lncRNA selected by different agents. (B) Agents targeting genome integrity clustered by shared predictive lncRNA 
signatures. One-sided Fisher exact test p values were indicated by different colors in the heatmap.  
These observations indicated that lncRNA-drug interactions may imply the underlying 
mechanism through which the cell lines respond to treatment. 
3.2.4 Construction of LncRNA-based EN regression Prediction (LENP) models 
Using the most predictive lncRNAs identified by the bootstrapping training, an LncRNA-based 
EN prediction model (LENP) was developed for each agent. The LENP models were built in pan-
cancer scale as well as in cancer-specific scale with sufficient cell lines (n > 15). The model 
performance was assessed by ten-fold cross-validation using Pearson’s correlation coefficient and 
Kendall’s 𝜏 of observed versus predicted IC50s. 
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Figure 8 LncRNA-based EN-Prediction Models Predict Drug Response in Cancer Cell Lines 
(A) Comparison of model performance between LENP training by AUC (y-axis) and LENP training by IC50s (x-axis) within 
agent categories. Each cross marker represents one agent. A regression line is drawn for each comparison. (B) Performance 
comparison between LENP and bootstrapping EN models for 265 drugs in pan-cancer and specific cancer types. Model 
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performance is shown on the y-axis. (C) LENP performance of pan-cancer models and cancer-specific models using top 
20 predictive lncRNAs for each agent. (D) Pan-cancer LENP performance for agents from different target pathways. 
Here, we refer to LENP models using IC50 values, but very similar results were obtained 
by using AUCs (Figure 8A). Compared to the previous bootstrapping procedure with all of the 
lncRNAs included, LENP models have a substantially increased performance in predicting the cell 
lines IC50s by using the top predictive lncRNAs (Figure 8B). The improved model performance 
indicated the EN regression’s power in identifying lncRNAs that are highly predictive to drug 
response.  
Overall, the pan-cancer LENP models reached a median performance at r = 0.55 (p < 10-
33, Pearson’s correlation), while the cancer-specific LENP models have a median performance at 
r = 0.71 (p < 10-6, Pearson’s correlation) (Figure 8C). Notably, compounds with higher pan-cancer 
performance are prone to be non-target agents that have a broader anti-cancer spectrum (Figure 
8D). 
 For instance, compounds targeting the cell cycle, genome integrity and mitosis have 
overall better performances than compounds targeting the ABL signaling and IGFR signaling in 
pan-cancer models. We also observed that some models built for targeted compounds have 
increased performance in cancer-specific models compared to pan-cancer models. For example, 
the LAML-specific model for imatinib, an ABL inhibitor and FDA approved leukemia medicine, 
had an elevated performance (r = 0.82, Pearson’s correlation) compared to the pan-cancer model 
in predicting the IC50s in leukemia cell lines (r = -0.09, Pearson’s correlation). 
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3.2.5 Independent validation of LENP model performance 
Next, I sought to validate the LENP models using an independent drug response data from the 
Cancer Cell Line Encyclopedia (CCLE) [2]. Among the 14 overlapped agents in both studies, 
LENP models successfully predicted the cell line response for 9 agents (p < 0.05, Spearman’s 
correlation), including paclitaxel (rho = 0.34, p = 0.0014, Spearman’s correlation) and 17-AAG 
(rho = 0.32, p = 4.6×10-7, Spearman’s correlation) (Figure 9A).  
For the other 5 agents, high proportion of censored IC50s in the original CCLE datasets 
may account for the sub-optimal validation in LENP models (Figure 9B). 
 
Figure 9 Independent validation using CCLE dataset 
(A) Prediction performance of EN models in CCLE data. The performance is assessed by Spearman correlation coefficients 
(x-axis) and -log10 transformed p value of real IC50s in CCLE versus predicted IC50s by lncRNA-based EN models. Label 
colors demonstrated the significance: the model with p value less than 0.05 is considered as having good independent 
validation performance. (B) Left: cumulative distribution of real CCLE IC50s in agents with good independent validation 
performance. Right: cumulative distribution of real CCLE IC50s in agents with poor independent validation performance. 
3.2.6 Discussion 
The study of lncRNAs’ role in cancer drug response has not gained much momentum due to the 
dearth of genomics/epigenetic platforms covering the non-coding region of the human genome 
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and the paucity of information regarding drug response in tumors. These bottlenecks have led the 
majority of lncRNA studies to use a “bottom-up” strategy by first determining each individual 
lncRNA’s downstream regulatory function and then investigating the lncRNA’s regulation of drug 
response in cancer. In this chapter, a “top-down” approach has been applied to construct the 
lncRNA-based drug response prediction models. The sparsity provided by EN regression greatly 
helps to identify the candidate lncRNAs under the condition where sample size (n) is far smaller 
than the feature number (p). Using bootstrapping aggregation, lncRNAs that may regulate drug 
response would be more frequently selected by the regression model. This analysis is totally data 
driven and does not require any priori biological knowledge. 
3.3 PREDICTING PATIENT THERAPEUTIC OUTCOMES VIA LENP 
The previous chapters have shown that cancer cell lines could recapitulate the lncRNA alterations 
in primary tumors. Therefore, in this chapter, the LENP models would be applied to 3,814 TCGA 
tumor lncRNA expression profile and predicted patient drug response across 21 cancer types. 
Since chemotherapy is widely used on advanced stage diseases, the prediction is restricted to 
patients with stage II (or later) disease except for LAML patients. 
3.3.1 Predicting known and novel drug indications 
For each patient, the tumor’s response is predicted for all of the 265 compounds. For each 
compound, the tumor’s response is classified as ‘sensitive’ or ‘resistant’ based on the rank of 
predicted IC50 by LENP models. Among 49 FDA approved drugs, 26 of them were predicted to 
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have a top 10 response rate in at least one cancer type that were approved for clinically use by 
FDA (Figure 10A).  
For example, Bleomycin is an FDA approved agent to treat head-neck squamous cell 
carcinoma (HNSC), uterine corpus endometrial carcinoma (UCEC), cervical squamous cell 
carcinoma and endocervical adenocarcinoma (CESC). Compared to an average response rate at 
23.8% of other cancer types, significant higher response rate to bleomycin were observed in 
patients with UCEC (response rate: 95.3%, p = 3.59 x 10-74), CESC (response rate: 55.5%, p = 
3.53 x 10-16), and HNSC (response rate: 38.5%, p = 0.06) (Figure 10B). Another example is 
Imatinib, an FDA approved agent for treating LAML. Based on LENP model, 100% of acute 
myeloid leukemia (LAML) patients are predicted to be imatinib sensitive (p = 2×10-15, two-tailed 
K-S test) (Figure 10C).   
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Figure 10 LncRNA-based EN-Prediction Models Predict Drug Response in Patient Tumors 
(A) Percentage of patients in each cancer type that are predicted to be sensitive/responsive to FDA-approved 
agents by lncRNA-based EN models. (B-D) Imatinib (left), bleomycin (middle), and gefitinib (right) were predicted to be 
sensitive in several cancer types using GSEA analysis. 
Interestingly, besides these FDA approved indications (i.e. drug-cancer type pairs), there 
are 46 out of 49 (93.9%) drugs that had proportion of ‘sensitive’ patients higher than 50% with 
cancers that were not approved by FDA. For example, approximately 74.2% of patients with 
glioblastoma (GBM) (p = 7.41 x 10-06, K-S test) and 99.1% of patients with low-grade glioma 
(LGG) (p = 3.96 x 10-60, K-S test) were predicted to be sensitive to Imatinib (Figure 10D). 
Although this drug is not currently approved by FDA to treat these two cancer types, phase II 
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clinical trials have been carried out to test the efficacy of imatinib in treating GBM and LGG [55, 
56].  
Together, these observations suggest that LENP models are capable of predicting both the 
known and novel drug response in patients. 
3.3.2 Associate the predicted drug response with therapeutic outcome 
Because the TCGA cancer patients were mostly treated based on standard chemotherapy protocol 
[41], I hypothesized that patients would have poor prognosis if they were predicted to be resistant 
to therapies. For 49 FDA approved therapeutic agents, 66 significant associations are observed 
between predicted drug resistance and significantly shorter survival in specific cancer types (p <= 
0.05, univariate Cox regression). Importantly, among 73 of FDA approved chemotherapy 
indications, 41 (56.2 %) of them have patients, who were predicted to be drug resistant, undergoing 
significantly poorer survival. 
3.3.3 Consensus drug resistance correlates with poor survival 
In clinic, patients usually take a combination of different drugs rather than single agents. Thus, to 
better study the chemotherapy response of cancer patients, each patient is given with a consensus 
drug response score by combining the prediction of first- and second-line chemotherapy that are 
approved by FDA for each cancer type. Using this heuristic method, a significant poor prognosis 
is observed for patients predicted to be chemotherapy resistant in THCA (Thyroid Carcinoma, p = 
0.045, two tailed Log-rank test), STAD (Stomach Adenocarcinoma, p = 0.015), BRCA (Breast 
Cancer, p = 0.063), and COAD-READ (Colorectal Cancer, p = 0.034) samples (Figure 11A).  
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Figure 11 LENP models could predict patient therapeutic outcome 
(A) The Kaplan-Meier curves of overall survival for patients grouped by different predicted responses to FDA-approved 
first- and second-line cancer drugs in four cancer types. (B) Forest plot of multivariate Cox regression analysis of “Drug 
resistance”, “Stage” and “Age at diagnosis” on patient survival in four cancer types. 
The improvement in prognosis is still significant after adjusting for known prognostic 
factors, e.g. age at diagnosis and disease stages, using multi-variate Cox regression model. 
Specifically, the predicted chemotherapy resistance remains to be significantly correlated with 
patients’ poor survival in THCA (hazard ratio = 1.76, p = 0.05), STAD (hazard ratio = 1.40, p = 
0.02) and COAD-READ (hazard ratio = 1.38, p = 0.08) (Figure 11B). 
3.3.4 Discussion 
As is shown in the previous chapters, cancer cell lines could highly recapitulate the lncRNAs 
alterations in primary tumors. In this chapter, by integrating the patient tumors genomics and 
clinical data, the cancer cell line based EN-models, i.e. LENP models, are shown to have the ability 
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in predicting the therapeutic responses in patients across different cancer types. Due to the 
complexity of chemotherapy that was given to each individual cancer patient, the patient overall 
survival are used to approximately represent chemotherapy outcome of the cancer patients. Further 
multivariate Cox regression model revealed that lncRNA based EN-models can predict patient 
survival in patient samples after adjusting for known prognostic factors such as age at diagnosis 
and disease stages.  
These analyses served as a proof of principle for using the non-coding genotype in cell-
line based panels to gain insights into precision cancer medicine. With the emerging of the 
pharmacogenomics data of standardly designed cancer precision medicine project like GENIE [57], 
we should be able to determine the performance of lncRNA based EN-models in patient tumor in 
short future. 
3.4 MECHANISM OF LNCRNAS IN REGULATING CANCER DRUG RESISTANCE 
LncRNAs have been reported to regulate the cancer drug resistance through regulating the protein-
coding genes involved in drug-metabolism and drug-target pathways[58, 59]. Since multi-drug 
resistance remains a major obstacle of successful chemotherapy in clinical treatment of primary 
and recurrent disease[60], I am particular interested in lncRNAs that are predictive to multi-drug 
response of agents with different mechanisms. Therefore, in this chapter, lncRNAs that may 
associate with multi-drug resistance would be identified by using a data-driven approach. Two 
different mechanism of lncRNAs in regulating cancer drug resistance would be proposed based on 
integrative co-expression and pathway analysis. 
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3.4.1 Drug resistance induced by lncRNAs through general pathways 
To get rid of imbalance agent numbers among different target categories, an entropy-based 
algorithm was designed to measure the extent of an lncRNA to be multi-drug response (MDR) 
related. Using this approach identified 221 MDR-related lncRNAs that are independent from drug 
target mechanism.  
To determine the possible functional roles of these lncRNAs, Gene Sets Enrichment 
Analysis (GSEA) [47]  was performed on the co-expression profile between lncRNAs and protein 
coding genes (Figure 12A). Strikingly, a significant correlation was observed between MDR 
lncRNAs and xenobiotic metabolism (p = 7.7×10-53, Spearman’s correlation) and glycolysis 
pathways (p = 2.06×10-47, Figure 12B).  
 
Figure 12 Identification of MDR-related lncRNAs 
(A) Distribution of the number of agents that multi-agent response (MDR) related lncRNAs are predictive to. The listed are 
top five lncRNAs predicting the greatest number of agents’ response in cell lines. (B) Correlation between the Shannon 
entropy of lncRNAs and their absolute normalized enrichment score across cancer hallmarks pathways. (C) Cumulative 
distribution of absolute NES in lncRNAs with high (low) Shannon entropy. Red (blue) denotes lncRNAs that have high (low) 
level of entropy. 
Interestingly, previous studies have highlighted the remarkable contribution of xenobiotic 
metabolism and glycolysis in inducing multi-drug resistance[61, 62]. Specifically, genes involved 
in xenobiotic metabolism (e.g. cytochrome P450 genes) could regulate the drug metabolism and 
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modulate the intracellular drug concentration, which would result in drug resistance and 
heterogeneous response among individual tumors[60-62]. 
3.4.2 LINC00992: an MDR-related lncRNA correlated with xenobiotic metabolism 
In total, this analysis identified 90 MDR related lncRNAs that are significantly correlated with 
xenobiotic metabolism (FDR < 0.25, GSEA) (Figure 13A). LINC00992 is identified as one of 
these MDR lncRNAs. LINC00992 is an intergenic lncRNA located on chromosome 5q23.1 and is 
expressed in multiple cancer types (Figure 13B).  
Being predictive to cell line response of 158 agents, LINC00992 exhibited significant 
positive expression correlation with CYP2J2 (r = 0.29, Pearson’s correlation, p < 0.001), CYP1A1 
(r = 0.21, Pearson’s correlation, p < 0.001) as well as several other genes involved in xenobiotic 
metabolism pathway (NES: 1.25, FDR < 0.01, GSEA) (Figure 13C). Cancer cell lines with high 
expression of LINC00992 and CYP genes showed resistance to 154 (97.4%) of the predictable 
agents.  
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Figure 13 LINC00992 as a potential MDR-related lncRNA 
(A) Marginal distribution of predictive score in pan-cancer models. The red (blue) color denotes MDR-related lncRNAs that 
are positively (negatively) associate with xenobiotic metabolism genes. The pie chart on the right indicates the ratio between 
two groups of lncRNAs. (B) The expression of LINC00992 in cancer patients and its association with patient survival. The 
upper boxplot indicates the expression (normalized counts) of LINC00992 in 21 cancer types. The lower heatmap indicates 
the hazard ratio given by univariate cox regression. The red (blue) indicates a positive (negative) hazard ratio. The size of 
the inner circle denotes the significance of hazard ratio. (C) The association among the high expression of LINC00992, genes 
in xenobiotic metabolism and the IC50s of top predictable agents across cancer cell lines. The upper heatmap shows the 
expression level from blue (low) to red (high) colors. The lower heatmap shows the IC50s from green (sensitive) to purple 
(resistant) colors. (D) The Kaplan-Meier curves of overall survival for patients grouped by LINC00992 expression level in 
BRCA and LIHC. 
Furthermore, elevated expression of LINC00992 associated with poor survival in patients 
of BRCA (p = 0.022, two-tailed Log-rank test), LIHC (p = 0.065), THCA (p = 0.024) and READ 
(p = 0.178) (Figure 13D). Interestingly, LINC00992 has been identified as a potential regulator of 
CYP genes, which play important roles in chemotherapy resistance in cancer[60] [63]. Therefore, 
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LINC00992 may serve as a novel biomarker and a potential master regulator for multi-drug 
resistance through xenobiotic metabolism. 
3.4.3 Drug resistance induced by lncRNAs through drug target pathways 
In addition to the drug metabolism pathways, our analysis also revealed lncRNAs that regulate the 
drug response directly through drug target pathways. I analyzed the enrichment pattern of top 
predictive lncRNAs from each agent and successfully identified a number of specific pathway 
enrichments (Figure 14). 
 
Figure 14 Association between predictive lncRNAs and cancer hallmark pathways 
Enrichment of top predictive lncRNAs for each agent in cancer hallmark pathways. The left panel lists the target information 
of the agents. The right panel shows the number of predictive lncRNAs that are significantly associated with cancer hallmarks. 
The significant association is cut at FDR < 0.25 by GSEA. 
For example, estrogen response pathway significantly correlated with expression of 14 out 
of 20 (70%) top predictive lncRNAs in the pan-cancer tamoxifen EN-model. The top predictive 
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lncRNAs for PARP1/2 inhibitor, including olaparib (FDA approved) and talazoparib (in clinical 
trial), demonstrated significant co-expression with genes in DNA repair (85% of top predictive 
lncRNAs for olaparib; 70% for talazoparib) and G2M checkpoint (85% for olaparib and 70% for 
talazoparib). Intriguingly, top lncRNAs of Bromodomain and Extra-Terminal (iBET) inhibitors 
are significantly correlated with MYC-related pathways (80% for iBET762 and 85%for JQ1). This 
is consistent with the previous reports that iBETs achieves therapeutic effect in multiple cancer 
types by targeting c-MYC pathway[64-70]. 
3.4.4 EPIC1: a top predictive lncRNA of BET inhibitor resistance 
The iBETs are a class of small molecules that could reversibly block the function of Bromodomain 
and Extra-Terminal motif (BET) protein family. The iBETs have been demonstrated to be a 
promising new therapy in several cancer types including breast cancer[68, 71]. These inhibitors 
displace BET bromodomain proteins such as BRD4 from chromatin by competing with their 
acetyl-lysine recognition modules, leading to inhibition of oncogenic transcriptional programs[72].  
Using LENP models, both Pan-Cancer and BRCA-specific LENP models can be predicted 
with high sensitivity and specificity (Figure 15A). Among the novel predictive features to BET 
inhibitors responses are RP11-275I4.4 and RP11-708B6.2 (top predictors of sensitivity), as well 
as EPIC1 (Figure 15B). 
EPIC1 is an intergenic lncRNA located on chromosome 22q13.31, which is highly 
overexpressed in 15 cancer types including BRCA (Figure 15C) and is selected as a top predictor 
by iBET in BRCA-specific models. Consistent with LENP model prediction, EPIC1 expression 
has a significant positive correlation with IC50s of iBET-762 in breast cancer cell lines (rho = 0.53, 
p = 0.002, Spearman’s correlation) (Figure 15D).  
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Figure 15 EPIC1 as a top predictor of iBET762 resistance in breast cancer cell lines 
(A) Comparison of EN-model predicted IC50 in ten iterations and observed IC50 for I-BET-762. Model performance in ten 
iterations for both pan-cancer and BRCA-specific models were demonstrated in the box plot. (B) EN model for I-BET-762 
in BRCA. The top curve shows observed IC50 of I-BET-762 in each cell line. The central heatmap shows the top predictive 
lncRNA expression in the model across all cell lines (x-axis). Bar plot (left): weight of the top predictive lncRNAs in the 
model for I-BET-762 sensitivity (bottom) or insensitivity (top). (C) EPIC1 expression across cell lines grouped by cancer 
types. (D) The expression of EPIC1 in cancer patients and its association with patient survival. The upper boxplot indicates 
the expression (normalized counts) of EPIC1 in 21 cancer types. The lower heatmap indicates the hazard ratio given by 
univariate cox regression. The red (blue) indicates a positive (negative) hazard ratio. The size of the inner circle denotes the 
significance of hazard ratio. (E) Joint-density plot showing the correlation between EPIC1 expression and IC50 of iBET762 
in pancan cell lines. The y-axis and the box plot on the left show the minus ln-transformed IC50 of iBET762 in pancan cell 
lines (blue) and the breast cancer cell lines (red). The x-axis and the box plot on the bottom show the log-transformed 
expression of EPIC1 in all of the cancer cell lines (blue) and the breast cancer cell lines (red).  
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3.5 EPIC1: VALIDATION OF A BET INHIBITOR RESISTANCE REGULATOR 
3.5.1 Expression profile of EPIC1 in 13 cancer cell lines 
Primers are designed to screen EPIC1’s expression in 13 cell lines using RT-PCR. According to 
the quantification analysis, EPIC1 is upregulated in MCF-7, BT-20, A2780-Cis, Hs578T, K562 
and T-47D cell lines (Figure 16). 
 
Figure 16 Endogenous expression level of EPIC1 in 13 cancer cell lines 
3.5.2 Overexpression of EPIC1 lead to iBET resistance 
The full-length human EPIC1 cDNA was cloned and overexpressed EPIC1 in MCF-7 breast 
cancer cells. The EPIC1 overexpressed cells were treated with two iBET inhibitors (i.e., iBET-
762 and JQ1) to determine the functional role of EPIC1 in iBET responses. In accordance with the 
LENP prediction, overexpression of EPIC1 significantly led to iBET-762 and JQ1 resistance in 
MCF-7 cells (Figure 17A and 17B). 
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Figure 17 Overexpression of EPIC1 leads to MCF-7 resistance to iBETs 
(A) Efficacy of EPIC1 knock down by individual and pooled siRNAs compared to control siRNA. (B) Growth inhibition 
curves for EPIC1 overexpression or control MCF-7 cells treated with BET inhibitor I-BET-762 (G) and JQ-1 (H). 
3.5.3 RNA-seq analysis: mechanism of EPIC1 in regulating iBET resistance 
To further explore the underlying mechanism of EPIC1 to regulate iBET resistance, RNA-seq 
analyses were performed in A2780, A2780-Cis, MCF-7 and Hs578T cells after EPIC1 knockdown 
with two EPIC1 siRNAs, individually or pooled (Figure 18A).  
Here, to exclude the possible siRNA off-target effects, only genes regulated in the same 
direction in all three transfections are focused. EPIC1 knockdown in breast and ovarian cancer 
cells resulted in significant expression change of 4,318 genes, which were significantly overlapped 
with EPIC1-correlated genes in 505 cancer cell lines (p < 0.0001, two-tailed Fisher’s exact test) 
(Figure 18B).  
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Figure 18 EPIC1 regulate the iBET resistance by interacting with MYC-related pathway 
(A) Efficacy of EPIC1 knock down by individual and pooled siRNAs compared to control siRNA. (B and C) Overlapped 
EPIC1-regulated genes/pathways between knockdown cell lines in RNA-seq analysis and 505 cell lines from GDSC. (D) 
down regulation of cMYC-targets in EPIC1 knockdown A2780-Cis and MCF-7 cell lines. (E) Expression alteration of 
cMYC-targets in EPIC1 knockdown cell lines. The red (blue) indicates an up (down) regulation.  
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Moreover, 16 out of 18 EPIC1-correlated pathways in 505 cancer cell lines are 
significantly regulated by EPIC1-knockdown (FDR < 0.25, GSEA) (Figure 18C). Among them, 
the MYC pathway/targets are prominent gene sets enriched with EPIC1-associated genes in both 
cancer cell lines and EPIC1-knockdown cells (Figure 18D and 18E).  
In another study of our group, we have mechanistically demonstrated that EPIC1 regulates 
MYC transcriptional activity by directly interacting with MYC protein. Overexpression of EPIC1 
increased MYC target expression and breast tumorigenesis in vitro and in vivo, which can be 
abolished by MYC knockdown [73]. Our observations suggest that EPIC1 is an oncogenic lncRNA 
and also plays an important role in promoting the resistance to iBETs by increasing MYC protein’s 
transcriptional activity. 
3.5.4 Discussion 
In this chapter, we have experimentally demonstrated that EPIC1, the top predictive lncRNA for 
iBET drug response, strongly regulates iBET resistance in breast cancer. The iBETs are a class of 
MYC inhibitors, which have been demonstrated to have great potential to be translated to clinic in 
several cancer types including BRCA[68, 71]. The success of targeting MYC by iBET[68, 72, 74], 
with only minor toxicity in patients[75], has potentiated iBETs as a very promising class of agents 
for cancer therapy. However, the resistance to iBET, which was recently reported in multiple 
cancer types such as leukemia and BRCA, has largely hindered their translation into clinic[69, 71, 
76]. Despite that tremendous effort has been invested to identify the underlying regulator and 
biomarker for iBETs resistance, the detailed mechanism remains elusive. Our results suggest that 
EPIC1 may regulate iBET resistance through increasing MYC protein’s transcriptional activity. 
Future mechanistic study is warranted to demonstrate this hypothesis.  
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4.0  CONCLUSIONS 
This study has integrated multi-dimensional pharmacogenomic data of 11,950 long noncoding 
RNAs (lncRNAs) and 265 anti-cancer agents across 5,605 tumors and 1,005 cancer cell lines. By 
implementing a machine learning-based regression approach, our analysis identified 162,327 
lncRNA-drug interactions that potentially regulate the drug resistance/sensitivity in cancer cell 
lines. The prediction model derived by top lncRNA-drug interactions in cancer cell lines, i.e. 
LENP models, could readily predict the therapeutic outcome in patients across 21 cancer types. 
Furthermore, through integrative lncRNA-pathway analysis, we revealed that lncRNA could 
regulate the drug response by either mediating drug metabolism or interacting with drug-target 
pathways. Particularly, via RNA-seq analysis and in vitro experiments, we have demonstrated that 
EPIC1, the top predictive lncRNA for BET inhibitors (iBETs) drug response, strongly regulates 
iBETs resistance in breast cancer through increasing the transcriptional activity of MYC protein.  
Collectively, this study showed a proof of principle for using non-coding genotypes in cell-
line based panels for precision cancer medicine. This landscape of non-coding pharmacogenomic 
interactions can serve as a comprehensive knowledgebase for investigating lncRNAs’ role in 
cancer drug response, and will greatly facilitate the identification of non-coding biomarkers for 
cancer precision therapy. 
 
 57 
APPENDIX A 
LIST OF ABBREVIATIONS 
Abbreviation Full Term 
ACC Adrenocortical carcinoma 
ALL Acute Lymphoblastic Leukaemia 
ANOVA Analysis of Variance 
iBET Bromodomain and Extra-Terminal motif protein inhibitor 
BLCA Bladder Urothelial Carcinoma 
BRCA Breast invasive carcinoma 
CESC Cervical squamous cell carcinoma and endocervical adenocarcinoma 
CCLE Cancer Cell Line Encyclopedia 
COAD/READ Colon and rectum adenocarcinoma 
EN Elastic net 
ESCA Esophageal carcinoma 
GBM Glioblastoma multiforme 
GSEA Gene Set Enrichment Analysis 
GDSC Genomics of Drug Sensitivity in Cancer 
HNSC Head and Neck squamous cell carcinoma 
KEGG Kyoto Encyclopedia of Genes and Genomes 
KIRC Kidney renal clear cell carcinoma 
LAML Acute Myeloid Leukemia 
LASSO Least absolute shrinkage and selection operator 
LENP LncRNA-based EN regression prediction model 
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LGG Brain Lower Grade Glioma 
LIHC Liver hepatocellular carcinoma 
LncRNAs Long non-coding RNAs 
LUAD Lung adenocarcinoma 
LUSC Lung squamous cell carcinoma 
mRNA Messenger RNA 
OV Ovarian serous cystadenocarcinoma 
PAAD Pancreatic adenocarcinoma 
PCG Protein coding gene 
PRAD Prostate adenocarcinoma 
READ Rectum adenocarcinoma 
RNA Ribonucleic Acid 
SKCM Skin Cutaneous Melanoma 
SNP Single Nucleotide Polymorphism 
STAD Stomach adenocarcinoma 
TCGA The Cancer Genome Atlas 
THCA Thyroid carcinoma 
UCEC Uterine Corpus Endometrial Carcinoma 
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